Personalized mRNA Cancer Vaccine Development Service

Personalized mRNA Cancer Vaccines

A personalized mRNA cancer vaccine research program starts with molecular features unique to an individual tumor. Selected antigen sequences are encoded in mRNA so researchers can study antigen expression, processing, presentation, and immune recognition in an appropriate experimental system.

The mRNA format can encode several candidate antigens in one construct and allows the sequence to be adapted as the evidence changes. Lipid nanoparticles can help protect mRNA from degradation and support cellular uptake in research systems. These characteristics make mRNA a flexible platform for comparing multi-antigen designs, but the quality of the final construct still depends on how well the upstream neoantigens were discovered and prioritized.

Tumor Neoantigens

Tumor neoantigen candidates can arise from single-nucleotide variants, insertions and deletions, gene fusions, abnormal transcripts, structural events, and tumor-specific translation. These changes can create peptide sequences that are absent from the corresponding normal cells and therefore suitable for antigen-recognition research.

The connection from an alteration to a vaccine candidate is not automatic. The workflow must determine whether the event is somatic, whether the altered sequence is expressed, whether it can produce a relevant peptide, and whether the peptide is compatible with the sample's HLA context. Broader discovery strategies can add structural, noncoding, transcript, or translation-level evidence when coding mutations alone do not provide a sufficient candidate set.

Matched tumor-normal sequencing helps distinguish somatic alterations from germline background and supports more focused neoantigen candidate selection.

How Personalized mRNA Cancer Vaccines Work in Research

The research sequence begins with candidate neoantigen selection. Selected sequences are arranged in an mRNA construct, and the formulated mRNA is taken up by cells in the chosen model. Cytoplasmic translation produces the encoded antigen sequence. The resulting peptides can be presented in an MHC class I or class II context and investigated for antigen-specific immune recognition in downstream research.

This mechanism explains why candidate selection, sequence design, and delivery preparation must be planned together. A formulation cannot compensate for a candidate that lacks somatic, expression, or presentation-related support, while a strong candidate still requires a construct and experimental system that can test the intended hypothesis.

Integrated Personalized mRNA Cancer Vaccine Development Solution

The service follows the same route as the research material: discover tumor-specific candidates, design a multi-neoantigen sequence, construct a DNA template, prepare the mRNA, formulate the mRNA-LNP, and complete the agreed research quality assessment. Each stage follows the evidence and project criteria established upstream.

1. Tumor neoantigen discovery — Select a discovery strategy based on the expected antigen sources, available specimens, and validation goals.
2. Neoantigen sequence design and optimization — Convert prioritized candidates into a project-specific multi-neoantigen construct design.
3. Plasmid construction and production for research — Build and prepare the DNA template required for the agreed downstream workflow.
4. mRNA production and purification for research — Generate the RNA by in vitro transcription, purify it, and assess agreed quality attributes.
5. mRNA-LNP formulation and preparation for research — Encapsulate the mRNA in a research formulation and perform formulation-related assessment.
6. Quality control and research delivery — Deliver the agreed research material, data, and documentation with stage-appropriate QC results.

Keeping these stages in one project preserves the link between candidate evidence and the sequence that is ultimately prepared. The design team can review construct constraints before synthesis, while the downstream team receives the sequence history, intended model, and quality criteria needed for research preparation.

Tumor Neoantigen Discovery

No single sequencing combination is appropriate for every tumor model. CD Genomics offers three discovery strategies that progressively expand the sources of candidate neoantigens. The choice should reflect the biological question rather than the amount of data alone.

Classic Strategy: WES + mRNA-seq

Matched tumor-normal whole-exome sequencing identifies coding somatic variants, including SNVs and InDels, while tumor mRNA sequencing evaluates expression and supports fusion or transcript-level events. This is a practical starting point when the research goal centers on conventional mutation-derived neoantigens.

The analysis covers somatic mutations, single-nucleotide variants (SNVs), insertions and deletions (InDels), and gene fusions. Adding tumor expression evidence helps narrow a broad exome alteration list before candidate prioritization and construct design. WES remains limited for noncoding changes and large structural variants, while mRNA-seq does not directly establish translation or peptide presentation.

Research example. Rojas et al., Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer, Nature, 2023. The study used tumor sequencing, expression evidence, HLA-aware candidate selection, and personalized RNA constructs to investigate neoantigen-specific T-cell responses. Its findings are external research results, not service performance data.

See the detailed case article: Three Neoantigen Discovery Strategies.

Whole-Genome Strategy: WGS + WES + mRNA-seq

This strategy adds whole-genome sequencing to the exome and transcriptome workflow. WGS broadens the search to structural variants, copy-number changes, noncoding regions, rearrangement breakpoints, and complex genomic events. WES reinforces coding-region analysis, and mRNA-seq shows whether selected events have transcript-level support.

The analysis covers mutations, SNVs, InDels, fusions, structural variants (SVs), copy-number variations (CNVs), and abnormal splice junctions. This expanded scope can identify candidate sources beyond conventional coding mutations, but it produces more data and requires more extensive interpretation and validation.

Combining genome-wide breadth with exome and RNA evidence can recover candidate sources that WES alone may miss. This is most useful when rearrangements, fusions, structural events, or noncoding changes are central to the model and the project can support additional analysis and validation.

Research examples. Newman et al., Genomes for Kids: The Scope of Pathogenic Mutations in Pediatric Cancer Revealed by Comprehensive DNA and RNA Sequencing, Cancer Discovery, 2021; and Choi et al., Integrated mutational landscape analysis of uterine leiomyosarcomas, Proceedings of the National Academy of Sciences, 2021. These studies used integrated WGS, WES, and RNA-seq to characterize coding, structural, fusion, copy-number, and transcript-level events. They support broader event discovery but were not neoantigen vaccine performance studies.

See the detailed case article: Three Neoantigen Discovery Strategies.

Integrated Translatome Strategy: WES + Long-Read RNA-seq + Ribo-seq

The translatome strategy extends the evidence chain from DNA alterations through full-length transcript information to translation-level evidence. Tumor WES and matched-normal WES identify somatic events, long-read RNA sequencing expands transcript and junction discovery, and ribosome profiling provides evidence that selected regions are being translated.

The analysis covers mutations, SNVs, InDels, abnormal junctions, fusions, and tumor-specific translation events. Long-read RNA sequencing expands transcript and junction discovery, while Ribo-seq can help identify translated noncanonical ORFs and help deprioritize candidates without detectable translation-level support under the tested conditions.

Translation-level evidence helps distinguish transcribed regions from those engaged by ribosomes and expands the search toward noncanonical reading frames. The added layer is particularly relevant to tumors with few conventional coding candidates, although ribosome occupancy still does not establish HLA presentation or T-cell recognition.

Research example. Ouspenskaia et al., Unannotated proteins expand the MHC-I-restricted immunopeptidome in cancer, Nature Biotechnology, 2022. The study showed that translated, unannotated open reading frames can contribute peptides to the MHC-I immunopeptidome, supporting candidate discovery beyond annotated protein-coding regions.

See the detailed case article: Three Neoantigen Discovery Strategies.

The sequencing amounts shown above are reference configurations. Final data volume, sample requirements, comparison design, and analysis scope should be confirmed according to tumor content, specimen quality, genome background, study objective, and downstream validation needs.

Strategy-specific WES, WGS, and RNA workflows can be coordinated through our whole-exome sequencing, whole-genome sequencing, and transcriptome sequencing services.

Neoantigen Sequence Design and Optimization

Prioritized neoantigens must be converted into a sequence that fits the intended research construct. Candidate integration considers antigen order, junction-related risks, sequence compatibility, coding-sequence characteristics, mRNA stability-related features, and the expression model. The design scope is adapted to the number and type of selected candidates rather than applying a fixed candidate count.

The resulting design links every included sequence to its discovery evidence and records construct-level considerations for review before synthesis. This reduces avoidable redesign at the plasmid or mRNA stage and gives downstream experiments a traceable connection to the original tumor events.

• Prioritized neoantigen candidate input and evidence review
• Multi-neoantigen arrangement and junction assessment
• Sequence compatibility and coding-sequence optimization
• Construct-oriented sequence review and design report

Plasmid Construction and Production for Research

After the sequence design is approved, the project can proceed from gene synthesis to vector construction, plasmid preparation, and agreed identity and quality assessment. The plasmid serves as the DNA template for subsequent research mRNA preparation.

Planning the template within the same project keeps the construct sequence, vector context, and downstream transcription requirements aligned. Vector format, preparation scale, and quality assessment are customized according to the research objective.

mRNA Production and Purification for Research

The prepared DNA template enters an in vitro transcription workflow, followed by purification, concentration or buffer preparation, and project-specific quality assessment. Reviews can address identity, integrity, purity, and concentration as appropriate to the requested research material.

Because construct design and template preparation occur upstream in the same workflow, the mRNA stage receives a defined sequence and intended use. Preparation and QC conditions are selected according to the construct design, requested preparation scale, and downstream research requirements.

mRNA-LNP Formulation and Preparation for Research

Purified research mRNA can proceed to LNP formulation, encapsulation, purification or concentration, and formulation-related quality assessment. Formulation parameters are customized according to the experimental model, preparation scale, and downstream handling requirements.

LNP preparation protects the mRNA and supports cellular delivery in the chosen research system.

Quality Control and Research Delivery

Quality assessment is matched to the stage delivered. Depending on the scope, the final package may document sequence identity, plasmid quality, mRNA integrity, purity, concentration, and formulation-related attributes, together with methods, results, and agreed data files.

The project can end after neoantigen discovery, sequence design, plasmid preparation, purified mRNA, or mRNA-LNP preparation. This staged structure lets researchers order only the work required for the next experiment while preserving the option to continue through the complete development path. Preparation scale and QC scope are confirmed during consultation.

Frequently Asked Questions

Plan Your Personalized mRNA Cancer Vaccine Research Project

Tell us about your tumor model, available tumor and matched-normal specimens, preferred neoantigen discovery strategy, candidate-selection goals, and the downstream plasmid, mRNA, or mRNA-LNP material you need. We will define a research workflow around the evidence required for your next decision.

Request a Custom Development Plan